Xenograft Model Antitumor Assays
"Xenograft Model Antitumor Assays" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
In vivo methods of screening investigative anticancer drugs, biologic response modifiers or radiotherapies. Human tumor tissue or cells are transplanted into mice or rats followed by tumor treatment regimens. A variety of outcomes are monitored to assess antitumor effectiveness.
| Descriptor ID |
D023041
|
| MeSH Number(s) |
E05.337.550.200.900 E05.624.850
|
| Concept/Terms |
Xenograft Model Antitumor Assays- Xenograft Model Antitumor Assays
- Tumor Xenograft Assay
- Xenograft Antitumor Assays
- Antitumor Assay, Xenograft
- Antitumor Assays, Xenograft
- Assay, Xenograft Antitumor
- Assays, Xenograft Antitumor
- Xenograft Antitumor Assay
- Antitumor Assays, Xenograft Model
|
Below are MeSH descriptors whose meaning is more general than "Xenograft Model Antitumor Assays".
Below are MeSH descriptors whose meaning is more specific than "Xenograft Model Antitumor Assays".
This graph shows the total number of publications written about "Xenograft Model Antitumor Assays" by people in this website by year, and whether "Xenograft Model Antitumor Assays" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2015 | 0 | 1 | 1 |
| 2016 | 0 | 5 | 5 |
| 2018 | 0 | 1 | 1 |
| 2019 | 0 | 5 | 5 |
| 2020 | 0 | 5 | 5 |
| 2021 | 0 | 4 | 4 |
| 2024 | 1 | 5 | 6 |
| 2025 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Xenograft Model Antitumor Assays" by people in Profiles.
-
Antitumor Activity and Biomarker Analysis for TROP2 Antibody-Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft Models. Clin Cancer Res. 2025 Feb 03; 31(3):573-587.
-
Utilizing Patient-Derived Xenografts to Model Precision Oncology for Biliary Tract Cancer. Clin Cancer Res. 2025 Jan 17; 31(2):387-402.
-
The Combination of Tumor-targeting Salmonella typhimurium A1-R Plus the Autophagy-inhibitor Chloroquine Synergistically Eradicates HT1080 Fibrosarcoma Cells In Vitro and In Vivo. In Vivo. 2025; 39(1):102-109.
-
Thiostrepton suppresses colorectal cancer progression through reactive oxygen species related endoplasmic reticulum stress. Toxicol Appl Pharmacol. 2025 Feb; 495:117221.
-
UBA1 inhibition sensitizes cancer cells to PARP inhibitors. Cell Rep Med. 2024 Dec 17; 5(12):101834.
-
Engraftment of a surrogate antigen onto tumor cell surface via pHLIP peptide to universally target CAR-T cell therapy to solid tumors. Cancer Lett. 2025 Jan 01; 608:217319.
-
CD28 Costimulation Augments CAR Signaling in NK Cells via the LCK/CD3?/ZAP70 Signaling Axis. Cancer Discov. 2024 Oct 04; 14(10):1879-1900.
-
Exercise-induced ?2-adrenergic Receptor Activation Enhances the Antileukemic Activity of Expanded ?d T-Cells via DNAM-1 Upregulation and PVR/Nectin-2 Recognition. Cancer Res Commun. 2024 05 13; 4(5):1253-1267.
-
Accurate and Safe Tumor Targeting of Orally-administered Salmonella typhimurium A1-R Leads to Regression of an Aggressive Fibrosarcoma in Nude Mice. In Vivo. 2024; 38(6):2601-2609.
-
Targeting HIF-activated collagen prolyl 4-hydroxylase expression disrupts collagen deposition and blocks primary and metastatic uveal melanoma growth. Oncogene. 2021 Aug; 40(33):5182-5191.